| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Change in fair value of related-party convertible note | - | - | - | 0 |
| Loss on equity method investment | - | - | - | 0 |
| Interest expense (including amounts with related parties)-Nonrelated Party | 26 | 5 | 18 | - |
| Other (expense) income, net | -187 | -278 | -41 | 12 |
| Total other expense, net | -11,679 | -21,020 | -65,471 | -5,499 |
| Loss before income taxes and noncontrolling interests | -67,309 | -92,305 | -129,900 | -85,752 |
| Income tax benefit | -35 | 269 | -234 | 0 |
| Net loss | -67,274 | -92,574 | -129,666 | -85,752 |
| Net loss attributable to noncontrolling interests, net of tax | -21 | -19 | -20 | -23 |
| Net loss attributable to immunitybio common stockholders | -67,253 | -92,555 | -129,646 | -85,729 |
| Net loss per immunitybio common share basic (in dollars per share) | -0.07 | -0.1 | -0.15 | -0.12 |
| Net loss per immunitybio common share - diluted (in dollars per share) | -0.07 | -0.1 | -0.15 | -0.14 |
| Weighted-average number of common shares used in computing net loss per share basic (in shares) | 946,601,000 | 888,216,000 | 853,162,000 | 695,895,000 |
| Weighted-average number of common shares used in computing net loss per share diluted (in shares) | 946,601,000 | 888,216,000 | 853,162,000 | 697,961,000 |
ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX)